French real-life efficacy of 1st line gefitinib in EGFR mutation-positive NSCLC in the prospective EPIDAURE study: Results by EGFR exon 19 Del and L858R mutation subtypes

Authors :: V. Rondeau
Maurice Pérol
M. Licour
B. Lemaire
Elizabeth Brambilla
Isabelle Monnet
Elizabeth Fabre
Jacques Cadranel
Jean-François Morère
Source :: Annals of Oncology. 27:vi429
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Hematology
03 medical and health sciences
Exon
0302 clinical medicine
Gefitinib
Egfr mutation
030220 oncology & carcinogenesis
Internal medicine
medicine
030212 general & internal medicine
Line (text file)
business
medicine.drug
L858r mutation

Full Text Access

Tools